Davide Bartolomeo Gissi1, Andrea Gabusi2, Achille Tarsitano3, Laura Luccarini2, Luca Morandi4, Lucio Montebugnoli2. 1. Department of Biomedical and Neuromotor Sciences (Head: Prof Lucio Montebugnoli), Section of Oral Sciences, University of Bologna, Italy. Electronic address: davide.gissi@unibo.it. 2. Department of Biomedical and Neuromotor Sciences (Head: Prof Lucio Montebugnoli), Section of Oral Sciences, University of Bologna, Italy. 3. Department of Biomedical and Neuromotor Sciences (Head: Prof Claudio Marchetti), University of Bologna, Section of Maxillo-facial Surgery at Policlinico S. Orsola-Malpighi, Bologna, Italy. 4. Department of Biomedical and Neuromotor Sciences (Head: Prof Maria Pia Foschini), Section of Anatomic Pathology at Bellaria Hospital, University of Bologna, Italy.
Abstract
PURPOSE: Recent studies have emphasized the role of podoplanin in oral lesions at risk of malignant transformation. We investigated a group of oral leukoplakias (OLs) to determine a possible relation between altered podoplanin expression and dysplasia, and to compare the results with those obtained by other, widely used biomarkers. MATERIALS AND METHODS: The population consisted of 40 consecutive patients with a clinical and histological diagnosis of OL. Thirty-two OLs did not show dysplasia, whereas eight lesions presented with dysplasia. Immunohistochemical expression of podoplanin, p53 and Ki67 was analyzed in all samples. RESULTS: All three biomarkers were positive in seven of eight dysplastic OLs. Among the 32 OLs without dysplasia, Ki67 and p53 showed positive values in 21 and 10 samples respectively, whereas podoplanin was positive in only one case. Multiple logistic regression showed that podoplanin was the most powerful variable (Chi square 9.77; p < .01) statistically related to the presence of dysplasia. In addition, podoplanin showed a higher specificity value (96.87%) than Ki67 (34.37%) and p53 (68.75%). CONCLUSION: Podoplanin seems to be a reliable means of discriminating lesions with epithelial dysplasia and could be introduced in routine practice as a marker to discriminate OLs at risk of developing cancer.
PURPOSE: Recent studies have emphasized the role of podoplanin in oral lesions at risk of malignant transformation. We investigated a group of oral leukoplakias (OLs) to determine a possible relation between altered podoplanin expression and dysplasia, and to compare the results with those obtained by other, widely used biomarkers. MATERIALS AND METHODS: The population consisted of 40 consecutive patients with a clinical and histological diagnosis of OL. Thirty-two OLs did not show dysplasia, whereas eight lesions presented with dysplasia. Immunohistochemical expression of podoplanin, p53 and Ki67 was analyzed in all samples. RESULTS: All three biomarkers were positive in seven of eight dysplastic OLs. Among the 32 OLs without dysplasia, Ki67 and p53 showed positive values in 21 and 10 samples respectively, whereas podoplanin was positive in only one case. Multiple logistic regression showed that podoplanin was the most powerful variable (Chi square 9.77; p < .01) statistically related to the presence of dysplasia. In addition, podoplanin showed a higher specificity value (96.87%) than Ki67 (34.37%) and p53 (68.75%). CONCLUSION:Podoplanin seems to be a reliable means of discriminating lesions with epithelial dysplasia and could be introduced in routine practice as a marker to discriminate OLs at risk of developing cancer.
Authors: Philipp Wolber; David Schwarz; Maximilian Niemczyk; Uta Drebber; Jens Peter Klußmann; Moritz Meyer Journal: Eur Arch Otorhinolaryngol Date: 2020-01-18 Impact factor: 2.503